Explore the vast range of titles available.

One of the most widespread additive manufacturing (AM) technologies is fused deposition modelling (FDM), also known as fused filament fabrication (FFF) or extrusion-based AM. The main reasons for its success are low costs, very simple machine structure, and a wide variety of available materials. However, one of the main limitations of the process is its accuracy and finishing. In spite of this, FDM is finding more and more applications, including in the world of micro-components. In this world, one of the most interesting topics is represented by microfluidic reactors for chemical and biomedical applications. The present review focusses on this research topic from a process point of view, describing at first the platforms and materials and then deepening the most relevant applications.

Pancreatic cancer, ranking as the third factor in cancer‐related deaths, necessitates enhanced diagnostic measures through early detection. In response, SiMoT‐Single‐molecule with a large Transistor multiplexing array, achieving a Technology Readiness Level of 5, is proposed for a timely identification of pancreatic cancer precursor cysts and is benchmarked against the commercially available chemiluminescent immunoassay SIMOA (Single molecule array) SP‐X System. A cohort of 39 samples, comprising 33 cyst fluids and 6 blood plasma specimens, undergoes detailed examination with both technologies. The SiMoT array targets oncoproteins MUC1 and CD55, and oncogene KRAS, while the SIMOA SP‐X planar technology exclusively focuses on MUC1 and CD55. Employing Principal Component Analysis (PCA) for multivariate data processing, the SiMoT array demonstrates effective discrimination of malignant/pre‐invasive high‐grade or potentially malignant low‐grade pancreatic cysts from benign non‐mucinous cysts. Conversely, PCA analysis applied to SIMOA assay reveals less effective differentiation ability among the three cyst classes. Notably, SiMoT unique capability of concurrently analyzing protein and genetic markers with the threshold of one single molecule in 0.1 mL positions it as a comprehensive and reliable diagnostic tool. The electronic response generated by the SiMoT array facilitates direct digital data communication, suggesting potential applications in the development of field‐deployable liquid biopsy. SiMoT‐Single‐Molecule with Large Transistor technology simultaneously analyzes protein and genetic markers, achieving a one‐molecule threshold in 0.1 mL. Benchmarking against SIMOA chemiluminescent ultrasensitive assay, SiMoT outperforms SIMOA in speed and overall performance. Moreover, SiMoT provides an electronic response, enhancing its suitability for direct digital data communication.

One of the main difficulties in developing a testing-and-diagnosis system for micro-manufacturing devices and machines is that the measurement process can require a high number of sensors, and is often too complex, in order to avoid external disturbances under normal working conditions, and the sensors are also not easy to allocate due to the minimal space available. At the present time, modern techniques of control-system engineering can be applied to propose a model-based testing and diagnosis methodology that reduces the number of the required sensors, due to a priori knowledge of the system expressed in terms of mathematical relationships between the physical variables. The Mechatronic Variable Estimation Library was created as a tool to estimate the value of “unknown” variables and parameters of the micro-device or machine using only a few sensors, reducing in this way the cost of the testing system and making the product of interest for industrial applications.

Liquid Biopsy Pancreatic cancer, ranked as the third‐leading cause of cancer‐related deaths, necessitates enhanced diagnostic measures through early detection. In response, SiMoT‐single‐molecule with a large transistor multiplexing array, achieving a technology readiness level of 5, is proposed in article number 2308141 by Eleonora Macchia, Luisa Torsi, and co‐workers for timely identification of pancreatic cancer precursor cysts and is benchmarked against the commercially available chemiluminescent immunoassay single molecule array (SIMOA) SP‐X system.